Skip to content
10-Q

Quarterly Report

Amylyx Pharmaceuticals, Inc. AMLX

0000950170-25-066363

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 28, 2025 89.14M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $17.93M
Current Liabilities Q1 2025 · Dec 31, 2024 $28.41M
Total Liabilities Q1 2025 · Mar 31, 2025 $18.26M
Total Liabilities Q1 2025 · Dec 31, 2024 $28.87M
Current Assets Q1 2025 · Mar 31, 2025 $216.14M
Current Assets Q1 2025 · Dec 31, 2024 $189.43M
Total Assets Q1 2025 · Mar 31, 2025 $219.68M
Total Assets Q1 2025 · Dec 31, 2024 $193.63M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $0
Cost Of Revenue Q1 2025 · Mar 31, 2024 $5.95M
Revenue Q1 2025 · Mar 31, 2025 $0
Revenue Q1 2025 · Mar 31, 2024 $88.64M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $77.39M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $170.55M
Shares Diluted Q1 2025 · Mar 31, 2024 67.85M sh
Capex Q1 2025 · Mar 31, 2024 $67K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$489K
Stockholders Equity Q1 2025 · Mar 31, 2024 $324.44M
Stockholders Equity Q1 2025 · Dec 31, 2023 $433.43M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.75
Eps Basic Q1 2025 · Mar 31, 2024 −$1.75
Sga Expense Q1 2025 · Mar 31, 2024 $57.76M
Rd Expense Q1 2025 · Mar 31, 2024 $36.61M
Net Income Q1 2025 · Mar 31, 2024 −$118.79M
Operating Income Q1 2025 · Mar 31, 2024 −$122.13M